来自Ganoderma lucidum合成的葡萄糖与体外低血糖活性之间的结构活性关系
Liu Yang1, Jia Huang2, Ni Huang3
1State Key Laboratory of Phytochemistry and Plant Resources in West China, Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, China.
International journal of biological macromolecules
|December 17, 2024
概括
这项研究探讨了合成葡萄糖及其与胰岛素的相互作用. 化合物2,一种特定的葡萄糖基结构,有效地增强胰岛素的分泌和稳定性,显示出作为降糖剂的潜力.
科学领域:
- 碳水化合物化学 碳水化合物化学
- 生物化学 生化学
- 药物设计 药物设计
背景情况:
- 具有定义结构的合成多糖类通过结构-活性关系 (SAR) 研究为药物设计提供了机会.
- 研究多糖蛋白相互作用,特别是与胰岛素的相互作用,对于理解蛋白质稳定性和开发新的治疗策略至关重要.
研究的目的:
- 报告有关胰岛素分泌的合成葡萄糖GLSWA-1及其子结构 (2-4) 的SAR.
- 阐明这些葡萄糖和胰岛素之间的相互作用背后的机制,重点关注蛋白质稳定性.
主要方法:
- 合成葡萄糖GLSWA-1及其子结构.
- 评估葡萄糖与胰岛素的结合亲和力.
- 在葡萄糖存在下评估胰岛素分泌和热稳定性.
- 分子动力学模拟以模拟葡萄糖-胰岛素相互作用.
主要成果:
- GLSWA-1和基结构2-4表现出不同程度的胰岛素结合.
- 化合物2表现出剂量依赖的胰岛素分泌的增强.
- 与GLSWA-1相比,化合物2为胰岛素提供了更好的热稳定性,这归因于更强的键.
- 分子动力学揭示了化合物2和胰岛素之间的"沟结合模型".
结论:
- 化合物2以其线性结构,灵活的 (1→6) - 葡萄糖化合物键,低分子量和最小的硬质阻碍为特征,是一种有前途的低血糖剂.
- 这项研究促进了对葡萄糖SAR与胰岛素热稳定性相关的理解.
- 这些发现凸显了专门设计的葡萄糖在针对胰岛素的治疗应用中的潜力.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
155
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
155
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168


